Reading CAMP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CAMP free→Reading CAMP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CAMP free→QuarterlyIQ Insights · CAMP
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Amendment to 2024 Equity Incentive Plan On June 10, 2026, at the annual meeting of stockholders (the “Annual Meeting”) of CAMP4 Therapeutics Corporation (the “Company”), the stockholders of the Company approved an amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan (the “2024 Plan”) to amend the evergreen provision to pro…
and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2026, the Board of Directors (the “ Board ”) of the CAMP4 Therapeutics Corporation (the “ Company ”) appointed Michael MacLean as a Class III director, effective April 1, 2026 (the “ Appointment Date ”). Mr. MacLean has also been appointed to the Audit Committee and Compensation Committee of the Board, effective on the Appointment Date…
and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a…
Entry into a Material Definitive Agreement. On December 22, 2025 (the “Effective Date”), CAMP4 Therapeutics Corporation (the “Company”) and ARE-MA Region No. 59, LLC (“ARE 59”) entered into the First Amendment (the “Lease Amendment”) to the Lease Agreement (the “Cambridge Lease”), dated October 3, 2019, by and between the Company and ARE 59. The term of the Cambridge Lease, which provides for approximately 30,760 square feet of laboratory and office space located at One Kendall Square, Cambri…
of this Current Report on Form 8-K by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: December 23, 2025
Entry into a Material Definitive Agreement On December 18, 2025, CAMP4 Therapeutics Corporation (the “Company”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC (“ Leerink Partners ”), relating to an offering of 5,000,000 shares (the “ Shares ”), of its common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per Share. All of the Shares are being sold by the Company. The Company estimates that the net pr…
Entry into a Material Definitive Agreement. On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”). Pursuant to the Agreement, the Company and GSK have agreed to collaborate on the research and development of antisense oligonucleotide (“ASO”) therapeutics targeting regulatory RNAs associated with multiple gene targets relevant to neuro…
Results of Operations and Financial Condition. On November 6, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On September 9, 2025, each of James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D. notified the Company’s board of directors (the “ Board ”) of their resignation as members of the Board, in each case, effective on that same date.
Entry into a Material Definitive Agreement Securities Purchase Agreement On September 9, 2025, CAMP4 Therapeutics Corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in up to two closings in a private placement transaction (the “ Private Placement ”). The initial closing o…
Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement set forth under
Results of Operations and Financial Condition. On August 14, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Results of Operations and Financial Condition. On May 13, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Results of Operations and Financial Condition. On March 27, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2025, the Board of Directors (the “ Board ”) of the CAMP4 Therapeutics Corporation (the “ Company ”) appointed Douglas Williams, PhD as a Class I director, and Murray Stewart, DM FRCP as a Class II director, in each case, effective March 17, 2025. Dr. Williams has also been appointed to the Audit Committee of the Board (the “ Audit Com…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.